Website Update: Email Subscriptions Discontinued

Posted by
  Website Update: Email Subscriptions Discontinued I want to share an important update regarding email subscriptions and newsletters on Arácnido Taxonomy. Effective immediately, I have discontinued using Mailchimp for email newsletter subscriptions. Over the past several days, the subscription system and associated website functions have been subjected to persistent automated bot activity and attempted exploitation. In addition to generating unwanted subscription activity, these requests have contributed to periods of reduced website performance. To help protect the website, its content, and legitimate visitors, the Mailchimp subscription and registration functions have been removed. Following Arácnido Taxonomy via RSS For the foreseeable future, RSS will be the primary way to subscribe to and follow new posts and updates from Arácnido Taxonomy. RSS provides a simple, direct way to receive new content without submitting an email address or creating an account. Once the Arácnido Ta...

Cobrotoxin suppresses TLR4-NF-κB/STAT1 signaling to mitigate glia-mediated neuroinflammation and motor deficits in Parkinson's disease

Posted by

 


Cobrotoxin suppresses TLR4-NF-κB/STAT1 signaling to mitigate glia-mediated neuroinflammation and motor deficits in Parkinson's disease

Abstract

Chronic neuroinflammation is implicated in the pathogenesis of Parkinson's disease (PD), contributing to progressive dopaminergic neuron loss. Cobrotoxin (CoTX), a short-chain α-neurotoxin isolated from Naja atra venom, exerts anti-inflammatory and analgesic effects in several inflammation-related disease models. However, whether CoTX modulates glia-mediated neuroinflammation or confers neuroprotection in PD remains unknown. In this study, we conducted a randomized, placebo-controlled clinical trial and preclinical animal studies to explore the therapeutic efficacy and mechanisms of CoTX in PD. A 12-day subcutaneous regimen of Cobratide (an injectable form of CoTX), consisting of 70 μg daily for 5 days, a 2-day interval, and another 5-day course, significantly improved motor symptoms in PD patients, as reflected by the UPDRS Part II + III scores, with a well-tolerated safety profile. These beneficial effects were further validated in both MPTP- and lipopolysaccharide-induced PD mouse models. Specifically, intranasal administration of CoTX ameliorated motor coordination defects, attenuated dopaminergic neuronal loss, and suppressed glia-mediated neuroinflammation in the substantia nigra of MPTP-challenged mice. Mechanistically, CoTX did not directly protect neurons; instead, it conferred indirect neuroprotection by inhibiting neuroinflammation via blockade of the NF-κB/STAT1 signaling cascades. Furthermore, CoTX functionally interacted with TLR4, which may act as a putative molecular target of CoTX. Collectively, these findings demonstrate the anti-neuroinflammatory and neuroprotective effects of CoTX in PD, highlighting its potential as a promising therapeutic candidate.
Yu, C., Ma, S., Cao, Y., Xu, D., Hou, X., Liu, C., Qin, Z., Luo, W., Wu, J., Liu, J., & Hu, L. (2026). Cobrotoxin suppresses TLR4-NF-κB/STAT1 signaling to mitigate glia-mediated neuroinflammation and motor deficits in Parkinson's disease. International Immunopharmacology, 188, 117322. https://doi.org/10.1016/j.intimp.2026.117322